Shorter J - Search Results

1

Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia.

Brown DG, Shorter J, Wobst HJ. Brown DG, et al. Among authors: shorter j. Bioorg Med Chem Lett. 2020 Feb 15;30(4):126942. doi: 10.1016/j.bmcl.2019.126942. Epub 2019 Dec 30. Bioorg Med Chem Lett. 2020. PMID: 31926785 Review.

2

TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity.

Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. Johnson BS, et al. Among authors: shorter j. J Biol Chem. 2009 Jul 24;284(30):20329-39. doi: 10.1074/jbc.M109.010264. Epub 2009 May 22. J Biol Chem. 2009. PMID: 19465477 Free PMC article.

3

Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis.

McGurk L, Mojsilovic-Petrovic J, Van Deerlin VM, Shorter J, Kalb RG, Lee VM, Trojanowski JQ, Lee EB, Bonini NM. McGurk L, et al. Among authors: shorter j. Acta Neuropathol Commun. 2018 Aug 29;6(1):84. doi: 10.1186/s40478-018-0586-1. Acta Neuropathol Commun. 2018. PMID: 30157956 Free PMC article.

4

Poly(ADP-ribose) Engages the TDP-43 Nuclear-Localization Sequence to Regulate Granulo-Filamentous Aggregation.

McGurk L, Gomes E, Guo L, Shorter J, Bonini NM. McGurk L, et al. Among authors: shorter j. Biochemistry. 2018 Dec 26;57(51):6923-6926. doi: 10.1021/acs.biochem.8b00910. Epub 2018 Dec 17. Biochemistry. 2018. PMID: 30540446 Free PMC article.

5

Phase separation of RNA-binding proteins in physiology and disease: An introduction to the JBC Reviews thematic series.

Shorter J. Shorter J. J Biol Chem. 2019 May 3;294(18):7113-7114. doi: 10.1074/jbc.REV119.007944. Epub 2019 Apr 4. J Biol Chem. 2019. PMID: 30948513 Free PMC article. Review.

6

The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.

Wobst HJ, Mack KL, Brown DG, Brandon NJ, Shorter J. Wobst HJ, et al. Among authors: shorter j. Med Res Rev. 2020 Jul;40(4):1352-1384. doi: 10.1002/med.21661. Epub 2020 Feb 11. Med Res Rev. 2020. PMID: 32043626 Free PMC article. Review.

7

The Sense of Targeting Nonsense-Mediated Decay in C9-ALS/FTD.

Odeh HM, Shorter J. Odeh HM, et al. Among authors: shorter j. Neuron. 2020 Apr 8;106(1):6-9. doi: 10.1016/j.neuron.2020.03.017. Neuron. 2020. PMID: 32272067 Free article.

8

Arginine-rich dipeptide-repeat proteins as phase disruptors in C9-ALS/FTD.

Odeh HM, Shorter J. Odeh HM, et al. Among authors: shorter j. Emerg Top Life Sci. 2020 Dec 11;4(3):293-305. doi: 10.1042/ETLS20190167. Emerg Top Life Sci. 2020. PMID: 32639008 Free PMC article. Review.

9

FUS and TDP-43 Phases in Health and Disease.

Portz B, Lee BL, Shorter J. Portz B, et al. Among authors: shorter j. Trends Biochem Sci. 2021 Jul;46(7):550-563. doi: 10.1016/j.tibs.2020.12.005. Epub 2021 Jan 11. Trends Biochem Sci. 2021. PMID: 33446423 Free PMC article. Review.

10

Open Access: A Role for p53 in c9ALS/FTD?

Fare CM, Shorter J. Fare CM, et al. Among authors: shorter j. Trends Genet. 2021 May;37(5):404-406. doi: 10.1016/j.tig.2021.01.008. Epub 2021 Feb 4. Trends Genet. 2021. PMID: 33551183

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters